<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jsms</journal-id><journal-title-group><journal-title xml:lang="ru">Journal of Siberian Medical Sciences</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Siberian Medical Sciences</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2542-1174</issn><publisher><publisher-name>Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of  Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31549/2542-1174-2025-9-2-7-18</article-id><article-id custom-type="elpub" pub-id-type="custom">jsms-1193</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Особенности экспрессии молекулярных шаперонов Hsp27 и Hsp90 при серозном раке яичников</article-title><trans-title-group xml:lang="en"><trans-title>Features of the expression of the molecular chaperones Hsp27 and Hsp90 in serous ovarian cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4378-6915</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайгородова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaigorodova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кайгородова Евгения Викторовна – д-р мед. наук, доцент, ведущий научный сотрудник отделения общей и молекулярной патологии; профессор кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики</p><p>Researcher ID: A-5400-2014</p><p>Scopus ID: 24778286000</p><p>634050, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Evgeniya V. Kaigorodova – Dr. Sci. (Med.), Associate Professor, Leading Researcher, Department of General and Molecular Pathology; Professor, Departments of Biochemistry and Molecular Biology with a Course of Clinical Laboratory Diagnostics</p><p>Researcher ID: A-5400-2014</p><p>Scopus ID: 24778286000</p><p>2, Moskovskiy trakt, Tomsk, 634050</p></bio><email xlink:type="simple">zlobinae@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6826-725X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалёв</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalev</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ковалёв Олег Игоревич – аспирант кафедры патологической анатомии</p><p>Researcher ID: ABC-8699-2020</p><p>Томск</p></bio><bio xml:lang="en"><p>Oleg I. Kovalev – Post-graduate Student, Departments of Pathological Anatomy</p><p>Researcher ID: ABC-8699-2020</p><p>Tomsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0961-7336</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грищенко</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Grishchenko</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грищенко Максим Юрьевич – канд. мед. наук, заведующий кафедрой хирургии с курсом мобилизационной подготовки и медицины катастроф; главный врач</p><p>Томск</p></bio><bio xml:lang="en"><p>Maxim Y. Grishchenko – Cand. Sci. (Med.), Head, Department of Surgery with a Сourse of Mobilization Training and Disaster Medicine; Chief Physician</p><p>Tomsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1195-4008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вторушин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vtorushin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вторушин Сергей Владимирович – д-р мед. наук, профессор, заместитель директора по научной работе и трансляционной медицине, руководитель отделения общей и молекулярной патологии; профессор кафедры патологической анатомии</p><p>Researcher ID: S-3789-2016</p><p>Томск</p></bio><bio xml:lang="en"><p>Sergey V. Vtorushin – Dr. Sci. (Med.), Professor, Deputy Director for Research and Translational Medicine, Head, Department of General and Molecular Pathology; Professor, Department of Pathological Anatomy</p><p>Researcher ID: S-3789-2016</p><p>Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России; ОГАУЗ «Томский областной онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University; Tomsk Regional Oncology Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>06</month><year>2025</year></pub-date><volume>0</volume><issue>2</issue><fpage>7</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кайгородова Е.В., Ковалёв О.И., Грищенко М.Ю., Вторушин С.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Кайгородова Е.В., Ковалёв О.И., Грищенко М.Ю., Вторушин С.В.</copyright-holder><copyright-holder xml:lang="en">Kaigorodova E.V., Kovalev O.I., Grishchenko M.Y., Vtorushin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://jsms.elpub.ru/jour/article/view/1193">https://jsms.elpub.ru/jour/article/view/1193</self-uri><abstract><sec><title>В в е д е н и е</title><p>В в е д е н и е . Рак яичников (РЯ) представляет вторую по частоте причину смерти от гинекологического рака, при этом серозный рак является наиболее распространенным и агрессивным типом из всех гистологических вариантов. Поиск новых биомаркеров и мишеней для таргетной терапии РЯ является актуальной задачей онкогинекологии. В последние годы внимание исследователей приковано к изучению белков теплового шока (Heat shock proteins – Hsp), которые представляют собой молекулярные шапероны, синтезирующиеся в ответ на стрессовые факторы, способствующие рефолдингу поврежденных белков и восстановлению их клеточных функций. Молекулярные шапероны участвуют в поддержании гомеостаза клетки, регуляции активности онкогенов и опухолевых супрессоров.</p></sec><sec><title>Ц е л ь</title><p>Ц е л ь . Изучить особенности экспрессии Hsp27 и Hsp90 при серозном РЯ в сравнении с пограничными опухолями, с учетом внутриклеточной локализации и потенциального диагностического значения этих маркеров.</p><p>М а т е р и а л ы и м е т о д ы . В исследование были включены 23 пациентки с впервые установленным серозным РЯ и 6 женщин с пограничными опухолями яичников I–IIIc стадии по FIGO (средний возраст 53,4 ± 8,1 года), проходившие лечение в Томском НИИ онкологии и/или Томском областном онкологическом диспансере. Материалом для исследования служили парафиновые блоки биопсийного и операционного материала опухолевой ткани, полученные на этапе лапароскопического хирургического стадирования до начала лечения. Методом иммуногистохимического (ИГХ) окрашивания определяли внутриклеточную локализацию Hsp27 и Hsp90 в опухолевых и стромальных клетках.</p></sec><sec><title>Р е з у л ь т а т ы</title><p>Р е з у л ь т а т ы . В ходе ИГХ исследования выявлено, что презентация Hsp27 в опухолевых клетках при подсчете по цитоплазме и ядру выше, чем в строме, в 10,48 и 7,41 раза соответственно; презентация Hsp90 в опухолевых клетках выше в цитоплазме и ядрах, чем в клетках стромы, в 40,42 и 86,67 раза соответственно. Количество Hsp27-положительных опухолевых клеток выше в 3,2 раза количества Hsp90-положительных опухолевых клеток в ткани серозной аденокарциномы яичников (р = 0,0006, критерий Вилкоксона). При пограничных опухолях яичников количество Hsp27- и Hsp90-положительных опухолевых клеток значимо меньше, чем при РЯ (критерий Манна – Уитни р &lt; 0,0001 и р = 0,0018 соответственно).</p></sec><sec><title>З а к л ю ч е н и е</title><p>З а к л ю ч е н и е . Значительная разница в презентации молекулярных шаперонов Hsp27 и Hsp90 в клеточных компартментах опухолевых и стромальных клеток, а также более чем четырехкратное увеличение данного маркера при серозной карциноме яичников, по сравнению с пограничными опухолями, указывают на диагностическую и прогностическую роль Hsp27 и Hsp90 при иммуногистохимической диагностике РЯ, а также перспективы таргетной терапии, направленной на модуляцию активности Hsp27 и Hsp90.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>I n t r o d u c t i o n</title><p>I n t r o d u c t i o n . Ovarian cancer (OC) represents the second most common cause of death from gynecologic cancer, with serous cancer being the most common and aggressive of all histologic variants. The search for new biomarkers and therapeutic targets for the OC treatment is an urgent task of gynecologic oncology. In recent years, researchers have focused their attention on the study of heat shock proteins (Hsps), which are molecular chaperones synthesized in response to stress factors exposure and contributing to the refolding of damaged proteins and restoring their cellular functions. Molecular chaperones are involved in maintaining cell homeostasis, regulating the activity of oncogenes and tumor suppressors.</p></sec><sec><title>A i m</title><p>A i m . To study the features of the Hsp27 and Hsp90 expression in serous OC compared with borderline ovarian tumors, taking into account the intracellular localization and the potential diagnostic value of these markers.</p><p>M a t e r i a l s a n d m e t h o d s . The study included 23 patients with newly diagnosed serous OC and 6 women with FIGO stage I–IIIC borderline ovarian tumors (mean age 53,4 ± 8,1 years) who were treated at the Tomsk Research Institute of Oncology and/or Tomsk Regional Oncological Center. The study objects were paraffin blocks from tumor tissue obtained during biopsy and surgery intervention during laparoscopic surgical staging before the treatment. The intracellular localization of Hsp27 and Hsp90 in tumor and stromal cells was determined by immunohistochemical (IHC) staining.</p></sec><sec><title>R e s u l t s</title><p>R e s u l t s . The IHC study revealed that the expression of Hsp27 in tumor cells, when calculated by cytoplasm and nucleus, is 10,48 and 7,41 times higher than in the stroma, respectively; the expression of Hsp90 in tumor cells is 40,42 and 86,67 times higher in cytoplasm and nuclei than in stromal cells, respectively. The count of Hsp27-positive tumor cells is 3,2 times higher than the count of Hsp90-positive tumor cells in tissue of ovarian serous adenocarcinoma (p = 0,0006, Wilcoxon test). In borderline ovarian tumors, the count of Hsp27- and Hsp90-positive tumor cells is significantly lower than in OC (p &lt; 0,0001 and p = 0,0018, respectively, Mann-Whitney test).</p></sec><sec><title>C o n c l u s i o n</title><p>C o n c l u s i o n . The significant difference in the expression of the molecular chaperones Hsp27 and Hsp90 in the cellular compartments of tumor and stromal cells, as well as a more than fourfold increase in this marker in serous ovarian carcinoma compared with borderline tumors show the diagnostic and prognostic role of Hsp27 and Hsp90 in the immunohistochemical diagnosis of OC, as well as the prospects of Hsp27 and Hsp90 activity modulation targeted therapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>молекулярные шапероны</kwd><kwd>Hsp27</kwd><kwd>Hsp90</kwd><kwd>серозный рак яичников</kwd><kwd>иммуногистохимия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>molecular chaperones</kwd><kwd>Hsp27</kwd><kwd>Hsp90</kwd><kwd>serous ovarian cancer</kwd><kwd>immunohistochemistry</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы выражают благодарность Центру коллективного пользования «Медицинская геномика» ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук» за возможность использования научного оборудования.</funding-statement><funding-statement xml:lang="en">The authors would like to thank the Center for Collective Use “Medical Genomics” (Tomsk National Research Medical Center, Russian Academy of Sciences) for the opportunity to use the scientific equipment.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors // Int. J. Women’s Health. 2019;11:287-299. DOI: 10.2147/IJWH.S197604.</mixed-citation><mixed-citation xml:lang="en">Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors // Int. J. Women’s Health. 2019;11:287-299. DOI: 10.2147/IJWH.S197604.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Torre L.A., Trabert B., DeSantis C.E. et al. Ovarian cancer statistics, 2018 // CA Cancer J. Clin. 2018;68(4):284-296. DOI: 10.3322/caac.21456.</mixed-citation><mixed-citation xml:lang="en">Torre L.A., Trabert B., DeSantis C.E. et al. Ovarian cancer statistics, 2018 // CA Cancer J. Clin. 2018;68(4):284-296. DOI: 10.3322/caac.21456.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Elias K.M., Guo J., Bast R.C. Jr. Early detection of ovarian cancer // Hematol. Oncol. Clin. North Am. 2018;32(6):903-914. DOI: 10.1016/j.hoc.2018.07.003.</mixed-citation><mixed-citation xml:lang="en">Elias K.M., Guo J., Bast R.C. Jr. Early detection of ovarian cancer // Hematol. Oncol. Clin. North Am. 2018;32(6):903-914. DOI: 10.1016/j.hoc.2018.07.003.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nebgen D.R., Lu K.H., Bast R.C. Jr. Novel approaches to ovarian cancer screening // Curr. Oncol. Rep. 2019;21(8):75. DOI: 10.1007/s11912-019-0816-0.</mixed-citation><mixed-citation xml:lang="en">Nebgen D.R., Lu K.H., Bast R.C. Jr. Novel approaches to ovarian cancer screening // Curr. Oncol. Rep. 2019;21(8):75. DOI: 10.1007/s11912-019-0816-0.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lucidi A., Buca D., Ronsini C. et al. Role of extracellular vesicles in epithelial ovarian cancer: A systematic review // Int. J. Mol. Sci. 2020;21(22):8762. DOI: 10.3390/ijms21228762.</mixed-citation><mixed-citation xml:lang="en">Lucidi A., Buca D., Ronsini C. et al. Role of extracellular vesicles in epithelial ovarian cancer: A systematic review // Int. J. Mol. Sci. 2020;21(22):8762. DOI: 10.3390/ijms21228762.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hrudka J., Jelínková K., Fišerová H. et al. Heat shock proteins 27, 70, and 110: Expression and prognostic significance in colorectal cancer // Cancers (Basel). 2021; 13(17):4407. DOI: 10.3390/cancers13174407.</mixed-citation><mixed-citation xml:lang="en">Hrudka J., Jelínková K., Fišerová H. et al. Heat shock proteins 27, 70, and 110: Expression and prognostic significance in colorectal cancer // Cancers (Basel). 2021; 13(17):4407. DOI: 10.3390/cancers13174407.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kaigorodova E.V., Bogatyuk M.V. Heat shock proteins as prognostic markers of cancer // Curr. Cancer Drug Targets. 2014;14(8):713-726. DOI: 10.2174/1568009614666140926122846.</mixed-citation><mixed-citation xml:lang="en">Kaigorodova E.V., Bogatyuk M.V. Heat shock proteins as prognostic markers of cancer // Curr. Cancer Drug Targets. 2014;14(8):713-726. DOI: 10.2174/1568009614666140926122846.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hu C., Yang J., Qi Z. et al. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities // MedComm(2020). 2022;3(3):e161. DOI: 10.1002/mco2.161.</mixed-citation><mixed-citation xml:lang="en">Hu C., Yang J., Qi Z. et al. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities // MedComm(2020). 2022;3(3):e161. DOI: 10.1002/mco2.161.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Langdon S.P., Rabiasz G.J., Hirst G.L. et al. Expression of the heat shock protein HSP27 in human ovarian cancer // Clin. Cancer Res. 1995;1(12):1603-1609.</mixed-citation><mixed-citation xml:lang="en">Langdon S.P., Rabiasz G.J., Hirst G.L. et al. Expression of the heat shock protein HSP27 in human ovarian cancer // Clin. Cancer Res. 1995;1(12):1603-1609.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng Q., Chang J.T., Geradts J. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer // Breast Cancer Res. 2012;14(2):R62.</mixed-citation><mixed-citation xml:lang="en">Cheng Q., Chang J.T., Geradts J. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer // Breast Cancer Res. 2012;14(2):R62.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors // Drug Discov. Today. 2008;13(1-2):38-43.</mixed-citation><mixed-citation xml:lang="en">Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors // Drug Discov. Today. 2008;13(1-2):38-43.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis // Trends Biochem. Sci. 2006;31(3):164-172.</mixed-citation><mixed-citation xml:lang="en">Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis // Trends Biochem. Sci. 2006;31(3):164-172.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bankhead P., Loughrey M.B., Fernández J.A. et al. QuPath: Open source software for digital pathology image analysis // Sci. Rep. 2017;7(1):16878. DOI: 10.1038/s41598-017-17204-5.</mixed-citation><mixed-citation xml:lang="en">Bankhead P., Loughrey M.B., Fernández J.A. et al. QuPath: Open source software for digital pathology image analysis // Sci. Rep. 2017;7(1):16878. DOI: 10.1038/s41598-017-17204-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C.C., Chou K.T., Hsu J.W. et al. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway // Int. J. Cancer. 2019;145(8):2144-2156. DOI: 10.1002/ijc.32301.</mixed-citation><mixed-citation xml:lang="en">Liu C.C., Chou K.T., Hsu J.W. et al. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway // Int. J. Cancer. 2019;145(8):2144-2156. DOI: 10.1002/ijc.32301.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kabakov A., Yakimova A., Matchuk O. Molecular chaperones in cancer stem cells: Determinants of stemness and potential targets for antitumor therapy // Cells. 2020; 9(4):892. DOI: 10.3390/cells9040892.</mixed-citation><mixed-citation xml:lang="en">Kabakov A., Yakimova A., Matchuk O. Molecular chaperones in cancer stem cells: Determinants of stemness and potential targets for antitumor therapy // Cells. 2020; 9(4):892. DOI: 10.3390/cells9040892.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mellier G., Liu D., Bellot G. et al. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27 // Cell Death Dis. 2013;4(10):e890. DOI: 10.1038/cddis.2013.413.</mixed-citation><mixed-citation xml:lang="en">Mellier G., Liu D., Bellot G. et al. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27 // Cell Death Dis. 2013;4(10):e890. DOI: 10.1038/cddis.2013.413.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lampros M., Vlachos N., Voulgaris S., Alexiou G.A. The role of Hsp27 in chemotherapy resistance // Biomedicines. 2022;10(4):897. DOI: 10.3390/biomedicines10040897.</mixed-citation><mixed-citation xml:lang="en">Lampros M., Vlachos N., Voulgaris S., Alexiou G.A. The role of Hsp27 in chemotherapy resistance // Biomedicines. 2022;10(4):897. DOI: 10.3390/biomedicines10040897.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Su J.M., Hsu Y.Y., Lin P., Chang H. Nuclear accumulation of heat-shock protein 90 is associated with poor survival and metastasis in patients with non-small cell lung cancer // Anticancer Res. 2016;36(5):2197-2203.</mixed-citation><mixed-citation xml:lang="en">Su J.M., Hsu Y.Y., Lin P., Chang H. Nuclear accumulation of heat-shock protein 90 is associated with poor survival and metastasis in patients with non-small cell lung cancer // Anticancer Res. 2016;36(5):2197-2203.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Stope M.B., Klinkmann G., Diesing K. et al. (2017). Heat shock protein HSP27 secretion by ovarian cancer cells is linked to intracellular expression levels, occurs independently of the endoplasmic reticulum pathway and HSP27's phosphorylation status, and is mediated by exosome liberation // Dis. Markers. 2017;2017:1575374. DOI: 10.1155/2017/1575374.</mixed-citation><mixed-citation xml:lang="en">Stope M.B., Klinkmann G., Diesing K. et al. (2017). Heat shock protein HSP27 secretion by ovarian cancer cells is linked to intracellular expression levels, occurs independently of the endoplasmic reticulum pathway and HSP27's phosphorylation status, and is mediated by exosome liberation // Dis. Markers. 2017;2017:1575374. DOI: 10.1155/2017/1575374.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Кайгородова Е.В., Рязанцева Н.В., Новицкий В.В. Апоптоз и белки теплового шока. Томск: Печатная мануфактура, 2012. 188 с.</mixed-citation><mixed-citation xml:lang="en">Kaigorodova E.V., Ryazantseva N.V., Novitsky V.V. (2012). Apoptosis and Heat Shock Proteins. Tomsk. 188 p. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
